Case against angioplasty and stenting of atherosclerotic renal artery stenosis

Circulation

Volumn 115, Issue 2, 2007, Pages 271-276

  Dworkin, Lance D ^a,c   Jamerson, Kenneth A ^b  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANGIOPLASTY; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE EXACERBATION; DYSLIPIDEMIA; HUMAN; HYPERTENSION; KIDNEY ARTERY STENOSIS; KIDNEY FUNCTION; PRIORITY JOURNAL; REVASCULARIZATION; RISK REDUCTION; STENT; TREATMENT OUTCOME; ARTERIOSCLEROSIS; NOTE; PATHOLOGY; RENAL ARTERY; RENOVASCULAR HYPERTENSION;

ARTERIOSCLEROSIS; HUMANS; HYPERTENSION, RENAL; RENAL ARTERY; RENAL ARTERY OBSTRUCTION; STENTS;

EID: 33846312840     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.619031     Document Type: Article

References (33)

1. Derkx FH, Schalekamp MA. Renal artery stenosis and hypertension. Lancet. 1994;344:237-239.
2. Ram CV. Renovascular hypertension. Curr Opin Nephrol Hypertens. 1997;6:575-579.
3. Webster J, Marshall F, Abdalla M, Dominiczak A, Edwards R, Isles CG, Loose H, Main J, Padfield P, Russell IT, Walker B, Watson M, Wilkinson R. Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. Scottish and Newcastle Renal Artery Stenosis Collaborative Group. J Hum Hypertens. 1998;12:329-335.
4. Plouin PF, Chatellier G, Darne B, Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group. Hypertension. 1998;31:823-829.
5. van Jaarsveld BC, Krijnen P, Pieterman H, Derkx FH, Deinum J, Postma CT, Dees A, Woittiez AJ, Bartelink AK, Man in 't Veld AJ, Schalekamp MA. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med. 2000;342:1007-1114.
6. Losito A, Fagugli RM, Zampi I, Parente B, de Rango P, Giordano G, Cao P. Comparison of target organ damage in renovascular and essential hypertension. Am J Hypertens. 1996;9:1062-1067.
7. Gobe GC, Axelsen RA, Searle JW. Cellular events in experimental unilateral ischemic renal atrophy and in regeneration after contralateral nephrectomy. Lab Invest. 1990;63:770-779.
8. Teunissen KE, Postma CT, van Jaarsveld BC, Derkx FH, Thien T. Endothelin and active renin levels in essential hypertension and hypertension with renal artery stenosis before and after percutaneous transluminal renal angioplasty. J Hypertens. 1997;15:1791-1796.
9. Meyrier A. Vascular mechanisms of renal fibrosis: vasculonephropathies and arterial hypertension. Bull Acad Natl Med. 1999;183:33-45.
10. Sos TA. Angioplasty for the treatment of azotemia and renovascular hypertension in atherosclerotic renal artery disease. Circulation. 1991;83(suppl):I-162-I-166.
11. O'Donovan RM, Gutierrez OH, Izzo JL Jr. Preservation of renal function by percutaneous renal angioplasty in high-risk elderly patients: short-term outcome. Nephron. 1992;60:187-192.
12. Caps MT, Perissinotto C, Zierler RE, Polissar NL, Bergelin RO, Tullis MJ, Cantwell-Gab K, Davidson RC, Strandness DE Jr. Prospective study of atherosclerotic disease progression in the renal artery. Circulation. 1998;98:2866-2872.
13. Suresh M, Laboi P, Mamtora H, Kalra PA. Relationship of renal dysfunction to proximal arterial disease severity in atherosclerotic renovascular disease. Nephrol Dial Transplant. 2000;15:631-636.
14. Farmer CK, Cook GJ, Blake GM, Reidy J, Scoble JE. Individual kidney function in atherosclerotic nephropathy is not related to the presence of renal artery stenosis. Nephrol Dial Transplant. 1999;14:2880-2884.
15. Textor SC. Ischemic nephropathy: where are we now? J Am Soc Nephrol. 2004;15:1974-1982.
16. Gray BH, Olin JW, Childs MB, Sullivan TM, Bacharach JM. Clinical benefit of renal artery angioplasty with stenting for the control of recurrent and refractory congestive heart failure. Vasc Med. 2002;7:275-279.
17. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202:1028-1034.
18. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group. Lancet. 1998;351:1755-1762.
19. Levey AS, Gassman JJ, Hall PM, Walker WG. Assessing the progression of renal disease in clinical studies: effects of duration of follow-up and regression to the mean: Modification of Diet in Renal Disease (MDRD) Study Group. J Am Soc Nephrol. 1991;1:1087-1094.
20. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
21. Tullis MJ, Caps MT, Zierler RE, Bergelin RO, Polissar N, Cantwell-Gab K, Davidson RC, Strandness DE Jr. Blood pressure, antihypertensive medication, and atherosclerotic renal artery stenosis. Am J Kidney Dis. 1999;33:675-681.
22. Kjeldsen SE, Westheim AS, Os I. INSIGHT and NORDIL: International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment: Nordic Diltiazem Study. Lancet. 2000;356:1929-1930.
23. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289:2073-2082.
24. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
25. Jackson B, Franze L, Sumithran E, Johnston CI. Pharmacologic nephrectomy with chronic angiotensin converting enzyme inhibitor treatment in renovascular hypertension in the rat. J Lab Clin Med. 1990;115:21-27.
26. Hricik DE, Browning PJ, Kopelman R, Goorno WE, Madias NE, Dzau VJ. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med. 1983;308:373-376.
27. van de Ven PJ, Beutler JJ, Kaatee R, Beek FJ, Mali WP, Koomans HA. Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease. Kidney Int. 1998;53:986-993.
28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
29. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38: UK Prospective Diabetes Study Group. BMJ. 1998;317:703-713.
30. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412. III). JAMA. 2001;285:2486-2497.
31. Lip GY, Edmunds E, Beevers DG. Should patients with hypertension receive antithrombotic therapy? J Intern Med. 2001;249:205-214. Review.
32. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1997;96:2751-2753.
33. Yusuf S. Two decades of progress in preventing vascular disease. Lancet. 2002;360:2-3.